when will there be a generic tirzepatide New Breakthrough Obesity Drug Tirzepatide — Amplify Aesthetics

For chronic weight management in adults with obesity, tirzepatide 15 mg delivered a mean 22.5% body weight reduction in the SURMOUNT-1 trial, compared to approximately 15% with semaglutide 2.4 mg in the STEP trials

The pattern of increasing receptor targets correlating with greater efficacy (and different dosing profiles) appears to be accelerating

Thyroid Safety Tirzepatide shares the FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies, leading to contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome

These conditions are associated with an increased risk of thyroid carcinoma and MEN 2 syndrome when using GLP-1 medications

But it is almost certainly caused by the downstream effects of the medication rather than the drug itself, and that distinction matters enormously when it comes to treatment

Is 50 units a lot at this concentration